Cited 8 times in
Prognostic factors of dose-response relationship for nodal control in metastatic lymph nodes of cervical cancer patients undergoing definitive radiotherapy with concurrent chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.contributor.author | 김귀언 | - |
dc.date.accessioned | 2022-12-22T04:10:09Z | - |
dc.date.available | 2022-12-22T04:10:09Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192060 | - |
dc.description.abstract | Objective: Regional control is occasionally unsatisfactory in cervical cancer, with the optimal radiation dose for nodal metastases in definitive radiotherapy (RT) with concurrent chemotherapy (CRT) remaining controversial. We investigated dose-response relationship for nodal local control in cervical cancer. Methods: We identified 115 patients with 417 metastatic nodes who received definitive CRT for cervical cancer with nodal metastases. External beam radiation therapy and brachytherapy plans were summated to determine total dose received by each node. Prognostic factors of nodal control and dose-response relationship were investigated using Cox-regression and restricted cubic spline function. Results: The 2-year progression-free survival rate was 69.4%. Among 43 patients with failures, 17 patients (37.5%) had regional failure included in first failure sites of which all except one were in-field only regional failures. Total 30 nodes showed recurrence at initial metastatic site after treatment. Neutrophil-to-lymphocyte ratio (NLR) ≥3.1, total radiation dose (minimum dose received by 98% of the target volume in equivalent dose in 2 Gy per fractions), and initial nodal volume ≥5.29 mL were poor prognostic factors (all p<0.050) of nodal local control. Restricted cubic spline functions revealed strongest dose-response relationship in high NLR (NLR ≥3.1) and initial nodal volume ≥5.29 mL subgroup. Conclusion: Initial nodal volume, radiation dose, and NLR were significant factors of nodal local control in cervical cancer; a stronger dose-response relationship was seen in bulky nodes with high NLR. Clinicians may consider these factors when determining the RT dose and the need for boost to nodal metastases in cervical cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Brachytherapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Nodes | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Uterine Cervical Neoplasms* | - |
dc.title | Prognostic factors of dose-response relationship for nodal control in metastatic lymph nodes of cervical cancer patients undergoing definitive radiotherapy with concurrent chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Won Hee Lee | - |
dc.contributor.googleauthor | Gwi Eon Kim | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.3802/jgo.2022.33.e59 | - |
dc.contributor.localId | A00744 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 35882603 | - |
dc.subject.keyword | Brachytherapy | - |
dc.subject.keyword | Cervical Cancer | - |
dc.subject.keyword | Dose | - |
dc.subject.keyword | Lymph Node | - |
dc.subject.keyword | Nodal Control | - |
dc.subject.keyword | Radiotherapy | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.citation.volume | 33 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | e59 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.33(5) : e59, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.